Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum

Kallol Bera, Aron Kamajaya, Amol V. Shivange, Anand K. Muthusamy, Aaron L. Nichols, Philip M. Borden, Stephen Grant, Janice Jeon, Elaine Lin, Ishak Bishara, Theodore M. Chin, Bruce N. Cohen, Charlene H. Kim, Elizabeth K. Unger, Lin Tian, Jonathan S. Marvin, Loren L. Looger, Henry A. Lester

Research output: Contribution to journalArticle

Abstract

The target for the “rapid” (<24 h) antidepressant effects of S-ketamine is unknown, vitiating programs to rationally develop more effective rapid antidepressants. To describe a drug’s target, one must first understand the compartments entered by the drug, at all levels—the organ, the cell, and the organelle. We have, therefore, developed molecular tools to measure the subcellular, organellar pharmacokinetics of S-ketamine. The tools are genetically encoded intensity-based S-ketamine-sensing fluorescent reporters, iSKetSnFR1 and iSKetSnFR2. In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively. The iSKetSnFR2 construct allows measurements at <0.3 μM S-ketamine. The iSKetSnFR1 and iSKetSnFR2 biosensors display >100-fold selectivity over other ligands tested, including R-ketamine. We targeted each of the sensors to either the plasma membrane (PM) or the endoplasmic reticulum (ER). Measurements on these biosensors expressed in Neuro2a cells and in human dopaminergic neurons differentiated from induced pluripotent stem cells (iPSCs) show that S-ketamine enters the ER within a few seconds after appearing in the external solution near the PM, then leaves as rapidly after S-ketamine is removed from the extracellular solution. In cells, S-slopes for the ER and PM-targeted sensors differ by <2-fold, indicating that the ER [S-ketamine] is less than 2-fold different from the extracellular [S-ketamine]. Organelles represent potential compartments for the engagement of S-ketamine with its antidepressant target, and potential S-ketamine targets include organellar ion channels, receptors, and transporters.

Original languageEnglish (US)
Article number499
JournalFrontiers in Cellular Neuroscience
Volume13
DOIs
StatePublished - Nov 12 2019

Fingerprint

Ketamine
Biosensing Techniques
Endoplasmic Reticulum
Pharmacokinetics
Cell Membrane
Induced Pluripotent Stem Cells
Dopaminergic Neurons
Ion Channels
Organelles
Antidepressive Agents
Ligands

Keywords

  • antidepressants
  • green fluorescent protein
  • inside-out pharmacology
  • iSketSnFR1
  • iSketSnFR2
  • organelles
  • periplasmic binding proteins (PBPs)
  • protein engineering and design

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Bera, K., Kamajaya, A., Shivange, A. V., Muthusamy, A. K., Nichols, A. L., Borden, P. M., ... Lester, H. A. (2019). Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. Frontiers in Cellular Neuroscience, 13, [499]. https://doi.org/10.3389/fncel.2019.00499

Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. / Bera, Kallol; Kamajaya, Aron; Shivange, Amol V.; Muthusamy, Anand K.; Nichols, Aaron L.; Borden, Philip M.; Grant, Stephen; Jeon, Janice; Lin, Elaine; Bishara, Ishak; Chin, Theodore M.; Cohen, Bruce N.; Kim, Charlene H.; Unger, Elizabeth K.; Tian, Lin; Marvin, Jonathan S.; Looger, Loren L.; Lester, Henry A.

In: Frontiers in Cellular Neuroscience, Vol. 13, 499, 12.11.2019.

Research output: Contribution to journalArticle

Bera, K, Kamajaya, A, Shivange, AV, Muthusamy, AK, Nichols, AL, Borden, PM, Grant, S, Jeon, J, Lin, E, Bishara, I, Chin, TM, Cohen, BN, Kim, CH, Unger, EK, Tian, L, Marvin, JS, Looger, LL & Lester, HA 2019, 'Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum', Frontiers in Cellular Neuroscience, vol. 13, 499. https://doi.org/10.3389/fncel.2019.00499
Bera, Kallol ; Kamajaya, Aron ; Shivange, Amol V. ; Muthusamy, Anand K. ; Nichols, Aaron L. ; Borden, Philip M. ; Grant, Stephen ; Jeon, Janice ; Lin, Elaine ; Bishara, Ishak ; Chin, Theodore M. ; Cohen, Bruce N. ; Kim, Charlene H. ; Unger, Elizabeth K. ; Tian, Lin ; Marvin, Jonathan S. ; Looger, Loren L. ; Lester, Henry A. / Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum. In: Frontiers in Cellular Neuroscience. 2019 ; Vol. 13.
@article{e92d4fadae8e4fdea4a832770da7819e,
title = "Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum",
abstract = "The target for the “rapid” (<24 h) antidepressant effects of S-ketamine is unknown, vitiating programs to rationally develop more effective rapid antidepressants. To describe a drug’s target, one must first understand the compartments entered by the drug, at all levels—the organ, the cell, and the organelle. We have, therefore, developed molecular tools to measure the subcellular, organellar pharmacokinetics of S-ketamine. The tools are genetically encoded intensity-based S-ketamine-sensing fluorescent reporters, iSKetSnFR1 and iSKetSnFR2. In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively. The iSKetSnFR2 construct allows measurements at <0.3 μM S-ketamine. The iSKetSnFR1 and iSKetSnFR2 biosensors display >100-fold selectivity over other ligands tested, including R-ketamine. We targeted each of the sensors to either the plasma membrane (PM) or the endoplasmic reticulum (ER). Measurements on these biosensors expressed in Neuro2a cells and in human dopaminergic neurons differentiated from induced pluripotent stem cells (iPSCs) show that S-ketamine enters the ER within a few seconds after appearing in the external solution near the PM, then leaves as rapidly after S-ketamine is removed from the extracellular solution. In cells, S-slopes for the ER and PM-targeted sensors differ by <2-fold, indicating that the ER [S-ketamine] is less than 2-fold different from the extracellular [S-ketamine]. Organelles represent potential compartments for the engagement of S-ketamine with its antidepressant target, and potential S-ketamine targets include organellar ion channels, receptors, and transporters.",
keywords = "antidepressants, green fluorescent protein, inside-out pharmacology, iSketSnFR1, iSketSnFR2, organelles, periplasmic binding proteins (PBPs), protein engineering and design",
author = "Kallol Bera and Aron Kamajaya and Shivange, {Amol V.} and Muthusamy, {Anand K.} and Nichols, {Aaron L.} and Borden, {Philip M.} and Stephen Grant and Janice Jeon and Elaine Lin and Ishak Bishara and Chin, {Theodore M.} and Cohen, {Bruce N.} and Kim, {Charlene H.} and Unger, {Elizabeth K.} and Lin Tian and Marvin, {Jonathan S.} and Looger, {Loren L.} and Lester, {Henry A.}",
year = "2019",
month = "11",
day = "12",
doi = "10.3389/fncel.2019.00499",
language = "English (US)",
volume = "13",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum

AU - Bera, Kallol

AU - Kamajaya, Aron

AU - Shivange, Amol V.

AU - Muthusamy, Anand K.

AU - Nichols, Aaron L.

AU - Borden, Philip M.

AU - Grant, Stephen

AU - Jeon, Janice

AU - Lin, Elaine

AU - Bishara, Ishak

AU - Chin, Theodore M.

AU - Cohen, Bruce N.

AU - Kim, Charlene H.

AU - Unger, Elizabeth K.

AU - Tian, Lin

AU - Marvin, Jonathan S.

AU - Looger, Loren L.

AU - Lester, Henry A.

PY - 2019/11/12

Y1 - 2019/11/12

N2 - The target for the “rapid” (<24 h) antidepressant effects of S-ketamine is unknown, vitiating programs to rationally develop more effective rapid antidepressants. To describe a drug’s target, one must first understand the compartments entered by the drug, at all levels—the organ, the cell, and the organelle. We have, therefore, developed molecular tools to measure the subcellular, organellar pharmacokinetics of S-ketamine. The tools are genetically encoded intensity-based S-ketamine-sensing fluorescent reporters, iSKetSnFR1 and iSKetSnFR2. In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively. The iSKetSnFR2 construct allows measurements at <0.3 μM S-ketamine. The iSKetSnFR1 and iSKetSnFR2 biosensors display >100-fold selectivity over other ligands tested, including R-ketamine. We targeted each of the sensors to either the plasma membrane (PM) or the endoplasmic reticulum (ER). Measurements on these biosensors expressed in Neuro2a cells and in human dopaminergic neurons differentiated from induced pluripotent stem cells (iPSCs) show that S-ketamine enters the ER within a few seconds after appearing in the external solution near the PM, then leaves as rapidly after S-ketamine is removed from the extracellular solution. In cells, S-slopes for the ER and PM-targeted sensors differ by <2-fold, indicating that the ER [S-ketamine] is less than 2-fold different from the extracellular [S-ketamine]. Organelles represent potential compartments for the engagement of S-ketamine with its antidepressant target, and potential S-ketamine targets include organellar ion channels, receptors, and transporters.

AB - The target for the “rapid” (<24 h) antidepressant effects of S-ketamine is unknown, vitiating programs to rationally develop more effective rapid antidepressants. To describe a drug’s target, one must first understand the compartments entered by the drug, at all levels—the organ, the cell, and the organelle. We have, therefore, developed molecular tools to measure the subcellular, organellar pharmacokinetics of S-ketamine. The tools are genetically encoded intensity-based S-ketamine-sensing fluorescent reporters, iSKetSnFR1 and iSKetSnFR2. In solution, these biosensors respond to S-ketamine with a sensitivity, S-slope = delta(F/F0)/(delta[S-ketamine]) of 0.23 and 1.9/μM, respectively. The iSKetSnFR2 construct allows measurements at <0.3 μM S-ketamine. The iSKetSnFR1 and iSKetSnFR2 biosensors display >100-fold selectivity over other ligands tested, including R-ketamine. We targeted each of the sensors to either the plasma membrane (PM) or the endoplasmic reticulum (ER). Measurements on these biosensors expressed in Neuro2a cells and in human dopaminergic neurons differentiated from induced pluripotent stem cells (iPSCs) show that S-ketamine enters the ER within a few seconds after appearing in the external solution near the PM, then leaves as rapidly after S-ketamine is removed from the extracellular solution. In cells, S-slopes for the ER and PM-targeted sensors differ by <2-fold, indicating that the ER [S-ketamine] is less than 2-fold different from the extracellular [S-ketamine]. Organelles represent potential compartments for the engagement of S-ketamine with its antidepressant target, and potential S-ketamine targets include organellar ion channels, receptors, and transporters.

KW - antidepressants

KW - green fluorescent protein

KW - inside-out pharmacology

KW - iSketSnFR1

KW - iSketSnFR2

KW - organelles

KW - periplasmic binding proteins (PBPs)

KW - protein engineering and design

UR - http://www.scopus.com/inward/record.url?scp=85076018830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076018830&partnerID=8YFLogxK

U2 - 10.3389/fncel.2019.00499

DO - 10.3389/fncel.2019.00499

M3 - Article

AN - SCOPUS:85076018830

VL - 13

JO - Frontiers in Cellular Neuroscience

JF - Frontiers in Cellular Neuroscience

SN - 1662-5102

M1 - 499

ER -